益生菌辅助治疗慢加急性肝衰竭后肠道菌群及预后观察

摘要/Abstract

摘要： 目的分析慢加急性肝衰竭(ACLF)患者加用益生菌治疗后的预后情况。方法选取我院84例ACLF患者,随机均分为两组。对照组常规治疗,观察组予以常规+肠道益生菌制剂治疗。观察治疗后患者菌群分布及生存情况。结果观察组治疗前乳酸杆菌、双歧杆菌数量(6.9±0.8)log₁₀nCFU/g、(5.5±0.9)log₁₀nCFU/g,大肠埃希菌、大肠杆菌数量(9.2±1.4)log₁₀nCFU/g、(8.8±0.4)log₁₀nCFU/g;治疗后乳酸杆菌、双歧杆菌数量分别为(8.4±0.6)log₁₀nCFU/g、(9.7±0.8)log₁₀nCFU/g,大肠埃希菌、大肠杆菌数量分别为(5.9±0.5)log₁₀nCFU/g、(6.1±0.4)log₁₀nCFU/g。对照组治疗前乳酸杆菌、双歧杆菌数量分别为(6.8±0.7)log₁₀nCFU/g、(5.4±0.8)log₁₀nCFU/g,大肠埃希菌、大肠杆菌数量分别为(9.0±1.3)log₁₀nCFU/g、(8.7±0.4)log₁₀nCFU/g;治疗后乳酸杆菌、双歧杆菌数量分别为(7.7±0.6)log₁₀nCFU/g、(7.6±0.8)log₁₀nCFU/g,大肠埃希菌、大肠杆菌数量分别为(6.8±0.5)log₁₀nCFU/g、(7.2±0.5)log₁₀nCFU/g。观察组治疗后乳酸、双歧杆菌数量更高,大肠杆菌、埃希菌则低于疗前和对照组(P<0.05)。观察组疗前CD4⁺、IL-6、IL-10水平分别为(32.8±5.4)%、(87.1±11.2)pg/mL、(31.8±4.4)pg/mL;治疗后CD4⁺、IL-6、IL-10水平分别为(44.7±2.4)%、(68.1±9.1)pg/mL、(20.5±3.4)pg/mL。对照组治疗前CD4⁺、IL-6、IL-10水平分别为(34.2±5.6)%、(90.2±9.0)pg/mL、(32.0±4.0)pg/mL;治疗后CD4⁺、IL-6、IL-10水平分别为(40.0±2.2)%、(75.4±10.2)pg/mL、(26.5±3.0)pg/mL。观察组治疗后CD4⁺水平显著升高(P<0.05),IL-6、IL-10低于疗前及对照组(P<0.05)。观察组治疗前GGT、ALT、AST、TBil水平分别为(62.3±10.5)U/L、(83.4±11.8)U/L、(98.2±21.0)U/L、(318.6±23.6)μmol/L;治疗后GGT、ALT、AST、TBil水平分别为(49.2±11.0)U/L、(59.6±9.2)U/L、(45.2±9.1)U/L、(158.6±18.6)μmol/L。对照组治疗前GGT、ALT、AST、TBil水平分别为(62.0±11.1)U/L、(84.5±11.5)U/L、(97.5±21.5)U/L、(314.5±20.3)μmol/L;治疗后GGT、ALT、AST、TBil水平分别为(53.7±12.3)U/L、(62.5±10.9)U/L、(48.5±9.2)U/L、(162.8±20.3)μmol/L。上述指标治疗后均低于治疗前(P<0.05)。观察组1年累计生存率为83.33%(35/42),对照组1年累计生存率为78.57%(33/42),两组比较差异无统计学意义差异(P>0.05)。结论对ACLF患者应用益生菌,可抑制患者肠道致病菌生长,提升免疫及肝功能,并改善预后。

关键词: 益生菌, 慢加急性肝衰竭, 肠道菌群, 预后, 肝功能

Abstract: Objective To evaluate the impact of probiotic adjuvant therapy on the gut microbiota compostion and clinical prognosis of patients with acute-on-chronic liver failure (ACLF). Methods In our hospital, 84 patients diagnosed with ACLF were randomly divided into two groups. The control group received conventional symptomatic treatment, while the observation group was treated with both conventional treatment and gut microbiota. The bacterial distribution, levels of immune factors [CD4⁺, CD8⁺], inflammatory factors,and liver function indicators [ALT, AST, GGT, TBil] between the two groups were compared. Both groups were followed up for 1 year to observe their survival rates. Results Before treatment, the number of lactobacillus and bifidobacteria in the observation group was (6.9±0.8) log₁₀nCFU/g, and (5.5±0.9) log₁₀nCFU/g, respectively, while the counts of Escherichia coli and coliforms were (9.2±1.4) log₁₀nCFU/g (8.8±0.4) log₁₀nCFU/g, respectively. After treatment, the counts of lactobacilli and bifidobacteria were (8.4±0.6) log₁₀nCFU/g, and (9.7±0.8) log₁₀nCFU/g, respectively, whereas the counts of Escherichia coli and coliforms were (5.9±0.5) log₁₀nCFU/g, and (6.1±0.4) log₁₀nCFU/g, respectively. For the control group, before treatment, the counts of lactobacillus and bifidobacteria were(6.8±0.7) log₁₀nCFU/g and (5.4 ± 0.8) log₁₀nCFU/g, respectively., The counts of Escherichia coli and coliforms were (9.0±1.3) log₁₀nCFU/g, and (8.7 ± 0.4) log₁₀nCFU/g, respectively. Post-treatment, lactobacilli and bifidobacteria counts were(7.7±0.6) log₁₀nCFU/g, (7.6±0.8) log₁₀nCFU/g, respectively, while Escherichia coli and coliforms counts were (6.8±0.5) log₁₀nCFU/g and (7.2±0.5) log₁₀nCFU/g, respectively. Post-treatment counts of lactobacilli and bifidobacteria in the observation group were significantly higher than their pre-treatment values and those in the control group. Conversely, the counts of Escherichia coli and coliforms were significantly lower post-treatment compared to pre-treatment and those in the control group (P<0.05). Before treatment, the levels of CD4⁺, IL-6 and IL-10 in the observation group were (32.8±5.4)%, (87.1±11.2) pg/mL and (31.8±4.4) pg/mL respectively. After treatment, the levels of GGT, alt, AST and TBil were(49.2±11.0)U/L, (59.6±9.2)U/L, (45.2±9.1)U/L, (158.6±18.6)μmol/L respectively. In the control group, the levels of GGT, ALT, AST and TBil before treatment were (62.04±11.18) U/L, (84.5±11.5) U/L, (97.5±21.5) U/L, (314.5±20.3) U/L, respectively μmol/L; After treatment, the levels of GGT, AST, AST and TBil were (53.7±12.3) U/L, (62.5 ±10.9) U/L, (48.5±9.2) U/L and (162.8±20.3)μmol/L, respectively. After treatment, liver function indices in both groups were significantly lower than their pre-treatment levels in the same group (P<0.05). The 1-year cumulative survival rate was 83.33% (35/42) in the observation group compared to 78.57% (33/42) in the control group. Conclusion The application of probiotics in ACLF patients can suppress the proliferation of harmful intestinal bacteria, enhance immune and liver functions, and potentially lead to better clinical outcomes.

Key words: Probiotics, Acute-on-chronic liver failure, gut microbiota, Prognosis, Liver function

程言明, 田芝奥, 李慧. 益生菌辅助治疗慢加急性肝衰竭后肠道菌群及预后观察[J]. 肝脏, 2023, 28(10): 1208-1211.

CHENG Yan-ming, TIAN Zhi-ao, LI Hui. Probiotic treatment in acute-on-chronic liver failure: insights into gut microbiota and patient prognosis[J]. Chinese Hepatolgy, 2023, 28(10): 1208-1211.

参考文献

[1] Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol, 2021,18(3):167-180.
[2] 林烨鸿, 林苏, 周卿, 等. 白细胞介素-6单核苷酸多态性与乙型肝炎病毒相关慢加急性肝衰竭发生与预后的相关性. 中华肝脏病杂志, 2019, 27(4):250-255.
[3] Wang QQ, Lv LX, Jiang HY, et al. Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats. Appl Microbiol Biotechnol. 2019,103(23):9673-9686.
[4] Gustot T, Stadlbauer V, Laleman W, et al. Transition to decompensation and acute-on-chronic liver failure: role of predisposing factors and precipitating events. J Hepatol, 2021,75(1):36-48.
[5] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志,2013,16(3):210-216.
[6] Cui BX, Lin L, Wang BM, et al. Therapeutic potential of saccharomyces boulardii in liver diseases: from passive bystander to protective performer. Pharmacol Res, 2022,17(5):106-112.
[7] Laleman W, Claria J, Merwe S, et al. Systemic inflammation and acute-on-chronic liver failure: too much, not enough. Can J Gastroenterol Hepatol, 2018,1(18):102-107.
[8] 董金玲, 李璐, 陈煜. 缓慢持续型慢加急性肝衰竭与慢性肝衰竭的甄别. 实用肝脏病杂志,2021,24(5):611-612.
[9] 黄涛, 田琼林, 张雪雪. 慢加急性肝衰竭继发细菌感染病原菌及预后评估. 中华医院感染学杂志,2022,32(6):861-865.
[10] Yating L, Longxian L, Jianzhong Y, et al. Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in D-galactosamine-treated rats. Appl Microbiol Biotechnol, 2019,103(1):375-393.
[11] Nielsen MC, Hvidbjerg GR, Claria J, et al. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells, 2020,9(5):1175-1176.
[12] Arab JP, Mateos RM, Shah VH, et al. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int, 2018,288(5):391-394.
[13] Casulleras M, Zhang IW, Lopez VC, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure. Cells, 2020,9(12):2632-2633.
[14] Jiachen L, Yantao X, Bimei J, et al. Novel insights into pathogenesis and therapeutic strategies of hepatic encephalopathy, from the Gut microbiota perspective. Front Cell Infect Microbiol, 2021,23(5):3369-3374.
[15] Ferstl P, Trebicka J. Acute decompensation and acute-on-chronic liver failure. Clin Liver Dis, 2021,25(2):419-430.
[16] 郑婷婷, 蒋珊珊, 方钟燎. 慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究. 实用肝脏病杂志,2018,21(6):899-902.
[17] Vasco M, Paolillo R, Schiano C, et al. Compromised nutritional status in patients with end-stage liver disease: role of gut microbiota. Hepatobiliary Pancreat Dis Int, 2018,17(4):290-300.
[18] Amin A, Mookerjee RP. Acute-on-chronic liver failure: definition, prognosis and management. Frontline Gastroenterol, 2019,11(6):458-467.
[19] Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut, 2022,71(1):148-155.
[20] 陈煜. 再论慢加急性肝衰竭新的临床分型及临床意义. 实用肝脏病杂志, 2020,23(4):457-458.